AULSF
Austar Lifesciences Limited, an investment holding company, engages in the provision of integrated engineering solutions to pharmaceutical manufacturers and research institutes in Mainland China and internationally. The company operates through Integrated Process and Packaging Equipment & Systems (IPS); Consulting, Digitalization and Construction (CDC); and Life Science Equipment and Consumables … Read more
AULSF (AULSF) - Net Assets
Latest net assets as of June 2025: $810.37 Million USD
Based on the latest financial reports, AULSF (AULSF) has net assets worth $810.37 Million USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($2.03 Billion) and total liabilities ($1.22 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $810.37 Million |
| % of Total Assets | 39.95% |
| Annual Growth Rate | 10.9% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 23.14 |
AULSF - Net Assets Trend (2020–2024)
This chart illustrates how AULSF's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for AULSF (2020–2024)
The table below shows the annual net assets of AULSF from 2020 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $793.47 Million | +2.32% |
| 2023-12-31 | $775.47 Million | -12.24% |
| 2022-12-31 | $883.58 Million | +12.07% |
| 2021-12-31 | $788.42 Million | +50.30% |
| 2020-12-31 | $524.57 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to AULSF's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 152.9% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $338.89 Million | 42.82% |
| Other Components | $452.52 Million | 57.18% |
| Total Equity | $791.41 Million | 100.00% |
AULSF Competitors by Market Cap
The table below lists competitors of AULSF ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
P2 Gold Inc
OTCQB:PGLDF
|
$9.50 Million |
|
Macro Metals Ltd
AU:M4M
|
$9.50 Million |
|
AGMO
KLSE:0258
|
$9.50 Million |
|
SIMPPLE LTD. Ordinary Shares
NASDAQ:SPPL
|
$9.50 Million |
|
Prestar Resources Bhd
KLSE:9873
|
$9.49 Million |
|
IRSA Propiedades Comerciales S.A
BA:IRCP
|
$9.48 Million |
|
Clean Teq Water Ltd
PINK:CNQQF
|
$9.48 Million |
|
Fibromat (M) Berhad
KLSE:0355
|
$9.48 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in AULSF's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 773,013,000 to 791,409,000, a change of 18,396,000 (2.4%).
- Net income of 16,079,000 contributed positively to equity growth.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $16.08 Million | +2.03% |
| Other Changes | $2.32 Million | +0.29% |
| Total Change | $- | 2.38% |
Book Value vs Market Value Analysis
This analysis compares AULSF's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.05x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | $1.01 | $0.07 | x |
| 2021-12-31 | $1.53 | $0.07 | x |
| 2022-12-31 | $1.75 | $0.07 | x |
| 2023-12-31 | $1.51 | $0.07 | x |
| 2024-12-31 | $1.54 | $0.07 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently AULSF utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 2.03%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 1.07%
- • Asset Turnover: 0.72x
- • Equity Multiplier: 2.63x
- Recent ROE (2.03%) is below the historical average (7.75%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | 6.39% | 2.55% | 0.94x | 2.66x | $-18.69 Million |
| 2021 | 35.25% | 13.76% | 0.99x | 2.60x | $198.64 Million |
| 2022 | 9.75% | 4.05% | 0.90x | 2.66x | $-2.23 Million |
| 2023 | -14.68% | -6.43% | 0.82x | 2.79x | $-190.77 Million |
| 2024 | 2.03% | 1.07% | 0.72x | 2.63x | $-63.06 Million |
Industry Comparison
This section compares AULSF's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $694,749,556
- Average return on equity (ROE) among peers: -25.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| AULSF (AULSF) | $810.37 Million | 6.39% | 1.50x | $9.49 Million |
| Advanced Biomedical Technologies Inc (ABMT) | $-4.46 Million | 0.00% | 0.00x | $14.18K |
| Abbott Laboratories (ABT) | $4.82 Billion | 39.04% | 1.31x | $191.37 Billion |
| Acarix AB (publ) (ACIXF) | $1.93 Million | -127.02% | 0.21x | $26.42 Million |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-72.62 Million | 0.00% | 0.00x | $4.05 Million |
| Adm Tronics Unltd (ADMT) | $-12.69K | 0.00% | 0.00x | $3.17 Million |
| Aethlon Medical Inc (AEMD) | $-3.07 Million | 0.00% | 0.00x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $732.88K |
| Adapthealth Corp (AHCO) | $2.07 Billion | 7.56% | 1.54x | $914.25 Million |
| Allied Healthcare Products Inc. (AHPIQ) | $8.88 Million | -33.95% | 1.22x | $726.24 |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $3.39 Million | -59.65% | 0.38x | $9.18 Million |